Meek T D
Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
J Enzyme Inhib. 1992;6(1):65-98. doi: 10.3109/14756369209041357.
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion. Accordingly, specific, exogenous inhibition of the HIV-1 protease is thought to be a viable approach for the development of novel therapeutics for the treatment of AIDS. Indeed, this hypothesis has been validated in virally-infected cell culture with synthetic inhibitors of HIV-1 protease. This chapter reviews the current status of the development of inhibitors of this enzyme.
人类免疫缺陷病毒(HIV)是获得性免疫缺陷综合征(AIDS)的病原体,它是一种逆转录病毒,利用病毒编码的天冬氨酸蛋白酶对其两种基因产物进行特定的蛋白水解加工,以便在成熟病毒粒子内形成活性酶和结构蛋白。因此,特异性、外源性抑制HIV-1蛋白酶被认为是开发治疗AIDS新疗法的一种可行方法。事实上,这一假说已在病毒感染的细胞培养中用HIV-1蛋白酶的合成抑制剂得到验证。本章综述了该酶抑制剂的研发现状。